- Home
- NUWE vs REVB Comparison
NUWE vs REVB Comparison
Compare NUWE & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUWE
- REVB
- Stock Information
- Founded
- NUWE 1999
- REVB 2020
- Country
- NUWE United States
- REVB United States
- Employees
- NUWE N/A
- REVB N/A
- Industry
- NUWE Biotechnology: Electromedical & Electrotherapeutic Apparatus
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- NUWE Health Care
- REVB Health Care
- Exchange
- NUWE Nasdaq
- REVB Nasdaq
- Market Cap
- NUWE 2.8M
- REVB 3.1M
- IPO Year
- NUWE N/A
- REVB N/A
- Fundamental
- Price
- NUWE $1.80
- REVB $0.80
- Analyst Decision
- NUWE Buy
- REVB
- Analyst Count
- NUWE 2
- REVB 0
- Target Price
- NUWE $17.00
- REVB N/A
- AVG Volume (30 Days)
- NUWE 7.3M
- REVB 1.3M
- Earning Date
- NUWE 11-11-2024
- REVB 11-08-2024
- Dividend Yield
- NUWE N/A
- REVB N/A
- EPS Growth
- NUWE N/A
- REVB N/A
- EPS
- NUWE N/A
- REVB N/A
- Revenue
- NUWE $8,969,000.00
- REVB N/A
- Revenue This Year
- NUWE $3.23
- REVB N/A
- Revenue Next Year
- NUWE $17.61
- REVB N/A
- P/E Ratio
- NUWE N/A
- REVB N/A
- Revenue Growth
- NUWE 3.66
- REVB N/A
- 52 Week Low
- NUWE $1.00
- REVB $0.70
- 52 Week High
- NUWE $31.15
- REVB $25.26
- Technical
- Relative Strength Index (RSI)
- NUWE 50.24
- REVB 44.03
- Support Level
- NUWE $1.55
- REVB $0.80
- Resistance Level
- NUWE $2.57
- REVB $1.05
- Average True Range (ATR)
- NUWE 0.51
- REVB 0.07
- MACD
- NUWE -0.02
- REVB -0.00
- Stochastic Oscillator
- NUWE 17.87
- REVB 9.69
About NUWE Nuwellis Inc.
Nuwellis Inc is a medical device company. Its solutions includes Aquadex Smartflow System and RenalSense Clarity RMS. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Clarity RMS is a kidney monitoring system that continuously measures urine output and flows, automatically displaying real-time data to the medical staff.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).